Shield shares rise again on positive activated factor twelve (AFT) results
This article was originally published in Clinica
Executive Summary
Shield Diagnostics' shares rose last week on news that its activated factor twelve (AFT) diagnostic test for cardiovascular disease was a more reliable indicator than simple cholesterol testing.